Mechanisms of selective autophagy
选择性自噬机制
基本信息
- 批准号:10240490
- 负责人:
- 金额:$ 32.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-12 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAmino AcidsAutophagocytosisAutophagosomeBindingBinding SitesC-terminalCellsChromosomesClear cell renal cell carcinomaCleaved cellComplexCytokinesisDataDigestionEventExcisionGenesGlycineHumanHydroxylationHypoxiaKidneyLaboratoriesLightLipidsMAP1 Microtubule-Associated ProteinMalignant NeoplasmsMediatingMediator of activation proteinMembraneMembrane MicrodomainsMetabolismModelingMolecularOncogenicPathologyPathway interactionsPeptidesPrimatesProcessProlineProteinsRegulationRenal carcinomaRoleSorting - Cell MovementStructureTSG101 geneTumor SuppressionTumor Suppressor GenesTumor Suppressor ProteinsVHL geneWorkangiogenesiscancer cellcancer therapycaveolin 1cholesterol-binding proteingene functiongene repressioninsightmembernovelprogramsprotein complexreceptorrecruitstemtheoriestranscription factortumortumor progression
项目摘要
In this proposal we investigate mechanism of selective autophagy in a novel, noncanonical pathway which has
tumor suppressing activity in renal cancer. Autophagy is a tightly regulated process of self-digestion, which in
cancer can have both tumor suppressing and oncogenic activities. Formation of an autophagosome requires
microtubule associated protein 1 light chains A, B and C (MAP1LC3A, B, C referred to as LC3A, B and C). LC3s
bind with cargo receptors through the LC3C-interacting regions (LIR) motifs on the receptors. Clear cell renal
cell carcinoma (ccRCC) is the most frequent renal cancer characterized by the loss the von Hippel-Lindau gene
(VHL). Loss of VHL function leads to activation of Hypoxia Inducible Transcription Factors (HIF) and changes in
angiogenesis and metabolism. Our laboratory discovered that VHL regulates autophagy. VHL inhibits LC3B
autophagy, which is oncogenic in ccRCC. In contrast, VHL induces tumor suppressing, LC3C autophagy in a
mechanism that involves removal of transcription repression by HIF. LC3C is an evolutionary late gene, present
only in higher primates and humans that evolved into multifaceted autophagic regulator, more complicated as
compared to LC3B/A. It maintains binding site for the canonical LIRs, similar to other LC3s, but it gained a new
binding site for LC3C-specific LIR, CLIR, and a highly conserved C-terminal, 20 amino acid peptide, cleaved in
the process of glycine lipidation. Our preliminary results show that LC3C autophagy requires novel non-canonical
pre- and -initiation complexes, which include ULK3, BECN1, UVRAG and PIK3C2A. We identified two direct
targets selectively degraded by LC3C autophagy: (i) Postdivision Midbody Rings (PDMBs), remnants of midbody
structures created during cytokinesis. PDMB accumulation in cancer cells promotes stem-like state and cancer
progression. (ii) Caveolin 1(CAV1), a lipid raft cholesterol-binding protein. We found that LC3C-dependent
degradation of the cargo requires C-terminal peptide on LC3C and a protein complex that includes adapter
proteins, TSG101 and CHMP2B. Surprisingly, VHL interacts with the core autophagy apparatus in an LC3C-
dependent manner, an indication that it directly serves in the formation of LC3C autophagosomes. In Aim 1, we
will determine activity of the LC3C preinitiation, initiation, and adapter complexes. We hypothesize that LC3C
autophagy is regulated by distinctive and selective mediators, as compared to LC3B, of the pre- and initiation
complexes and TSG101 anchors LC3C to the selective cargo. In Aim 2 we will determine the direct role of VHL
in regulation of LC3C autophagy. We propose that VHL anchors at the LC3C regulatory complex through the
hydroxylated proline in the C-terminal peptide and is necessary for the association with the core autophagic
proteins. In Aim 3 we will determine the role of unique structures of LC3C in the selective degradation of cargo
by the non-canonical pathway and in tumor suppressing activity of LC3C. We hypothesize that this process
requires the evolutionary recent C-terminal peptide.
在这个提议中,我们研究了一种新的非经典途径中的选择性自噬机制,
肾癌的肿瘤抑制活性。自噬是一种严格调控的自我消化过程,
癌症可以具有肿瘤抑制和致癌活性。自噬体的形成需要
微管相关蛋白1轻链A、B和C(MAP 1 LC 3 A、B、C称为LC 3 A、B和C)。LC 3s
通过受体上的LC 3C相互作用区(LIR)基序与货物受体结合。透明细胞肾
细胞癌(ccRCC)是最常见的肾癌,其特征在于von Hippel-Lindau基因的丢失
(VHL). VHL功能的丧失导致缺氧诱导转录因子(HIF)的激活和VHL基因表达的改变。
血管生成和代谢。我们的实验室发现VHL调节自噬。VHL抑制LC 3B
自噬,其在ccRCC中是致癌的。相比之下,VHL诱导肿瘤抑制,LC 3C自噬在一个细胞中,
这一机制涉及通过HIF消除转录抑制。LC 3C是一个进化晚期基因,存在于
只有在高等灵长类动物和人类进化成多方面的自噬调节器,更复杂的是,
与LC 3B/A相比。与其他LC 3类似,它保留了典型LIR的结合位点,但它获得了一个新的
LC 3C特异性LIR、CLIR的结合位点和高度保守的C末端20个氨基酸肽,在
甘氨酸脂化的过程。我们的初步结果表明,LC 3C自噬需要新的非经典的
前-和-起始复合物,其包括ULK 3、BECN 1、UVRAG和PIK 3C 2A。我们发现了两个
通过LC 3C自噬选择性降解的靶标:(i)分裂后中间体环(PDMB),中间体的残余物
细胞质分裂过程中产生的结构。癌细胞中PDMB的积累促进干细胞样状态和癌症
进展(ii)Caveolin 1(CAV 1)是一种脂筏胆固醇结合蛋白。我们发现LC 3C依赖性
货物的降解需要LC 3C上的C-末端肽和包括衔接子的蛋白质复合物
蛋白质,TSG 101和CHMP 2B。令人惊讶的是,VHL与LC 3C-3中的核心自噬装置相互作用。
依赖性的方式,这表明它直接在LC 3C自噬体的形成。目标1:
将决定LC 3C预起始、起始和衔接子复合物的活性。我们假设LC 3C
与LC 3B相比,自噬由独特的和选择性的介体调节,
TSG 101将LC 3C锚定至选择性货物。在目标2中,我们将确定VHL的直接作用
LC 3C自噬的调控。我们认为,VHL锚定在LC 3C调控复合物,通过
羟化脯氨酸的C-末端肽,是必要的协会与核心自噬
proteins.在目标3中,我们将确定LC 3C的独特结构在货物的选择性降解中的作用
通过非经典途径和LC 3C的肿瘤抑制活性。我们假设这个过程
需要进化最近的C末端肽。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria F Czyzyk-Krzeska其他文献
Maria F Czyzyk-Krzeska的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria F Czyzyk-Krzeska', 18)}}的其他基金
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 32.1万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 32.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 32.1万 - 项目类别: